v3.25.2
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting Information [Line Items]            
Research and development personnel expense $ 2,447,286   $ 1,730,444   $ 4,035,767 $ 3,269,555
General and administrative personnel expense 1,503,497   1,351,580   2,762,006 2,622,067
Total 3,933,918 $ 2,834,405 3,010,326 $ 2,726,381 6,768,323 5,736,707
Reportable Segment, Aggregation before Other Operating Segment [Member]            
Segment Reporting Information [Line Items]            
Preclinical, clinical trial and other costs 2,142,229   1,261,720   3,339,263 2,293,001
Administrative and facilities expense [1] 875,167   905,960   1,459,839 1,657,658
Other income, net 16,865   71,698   29,450 154,915
Total 3,933,918   3,010,326   6,768,323 5,736,707
Reportable Segment, Aggregation before Other Operating Segment [Member] | Employees [Member]            
Segment Reporting Information [Line Items]            
Research and development personnel expense [2] 305,057   468,724   696,504 976,554
General and administrative personnel expense [3] $ 628,330   $ 445,620   $ 1,302,167 $ 964,409
[1] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[2] Research and development personnel costs include employee stock-based compensation expense of $8,613 and $45,583 for the three months ended June 30, 2025 and 2024, respectively, and $55,333 and $76,704 for the six months ended June 30, 2025 and 2024, respectively.
[3] General and administrative personnel costs include employee stock-based compensation expense of $122,655 and $40,309 for the three months ended June 30, 2025 and 2024, respectively, and $245,310 and 79,180 for the six months ended June 30, 2025 and 2024, respectively, and are net of reimbursements received from CorLyst, LLC.